|
|
Volumn 7, Issue 7, 2010, Pages 358-
|
|
Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE TRIPHOSPHATE;
CAPECITABINE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
LAPATINIB;
ONCOPROTEIN;
PROTEIN P95;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BINDING SITE;
BREAST TUMOR;
CANCER COMBINATION CHEMOTHERAPY;
CANCER INHIBITION;
DOWN REGULATION;
DRUG EFFICACY;
DRUG TARGETING;
ENZYME ACTIVATION;
GENE;
HUMAN;
MONOTHERAPY;
NONHUMAN;
ONCOGENE NEU;
OVERALL SURVIVAL;
P95 GENE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN BINDING;
PROTEIN EXPRESSION;
PROTEIN PHOSPHORYLATION;
TREATMENT RESPONSE;
|
|
EID: 77954222472
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2010.93 Document Type: Article |
|
Times cited : (3)
|
|
References (1)
|
